Rep. David Taylor Buys Medpace Holdings, Inc. (NASDAQ:MEDP) Stock

Representative David Taylor (Republican-Ohio) recently bought shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on March 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Medpace stock on February 26th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Fifth Third Bancorp (NASDAQ:FITB) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 2/26/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Marathon Petroleum (NYSE:MPC) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 2/26/2026.
• Sold $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 2/26/2026.
• Sold $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 2/26/2026.

Medpace Price Performance

NASDAQ MEDP opened at $478.54 on Tuesday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The firm has a market capitalization of $13.58 billion, a P/E ratio of 31.28, a P/E/G ratio of 2.26 and a beta of 1.44. The business’s 50-day simple moving average is $532.11 and its 200-day simple moving average is $539.65.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s revenue was up 32.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC grew its holdings in Medpace by 7.0% during the 4th quarter. Corient Private Wealth LLC now owns 1,830 shares of the company’s stock valued at $1,029,000 after purchasing an additional 120 shares in the last quarter. Hsbc Holdings PLC acquired a new position in Medpace in the 4th quarter worth $2,164,000. Worthington Financial Partners LLC purchased a new position in Medpace in the 4th quarter valued at about $1,082,000. Bayban purchased a new position in Medpace in the 4th quarter valued at about $44,000. Finally, Pacer Advisors Inc. grew its stake in shares of Medpace by 38.1% during the fourth quarter. Pacer Advisors Inc. now owns 153,652 shares of the company’s stock valued at $86,299,000 after acquiring an additional 42,362 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Leerink Partners dropped their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Royal Bank Of Canada started coverage on shares of Medpace in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Mizuho set a $582.00 price objective on Medpace in a research report on Wednesday, February 11th. Finally, Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective on the stock in a research note on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $486.67.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.